Biomarkers and methods of treating pd-1 and pd-l1 related conditions
AssigneeGenentech, Inc.
InventorsMarcin Kowanetz, Daniel Shin-Yu Chen, Hartmut Koeppen
Life of this patent
Estimating the term…
Abstract
Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
Claims30
A method for treating a cancer in an individual comprising administering to the individual an effective amount of an anti-PD-L1 antibody every three weeks, wherein the anti-PD-L1 antibody comprises the following hypervariable regions (HVRs):
- (SEQ ID NO:
- 15)
- (a) an HVR-H1 sequence of GFTFSDSWIH;
- (SEQ ID NO:
- 16)
- (b) an HVR-H2 sequence of AWISPYGGSTYYADSVKG;
- (SEQ ID NO:
- 3)
- (c) an HVR-H3 sequence of RHWPGGFDY;
- (SEQ ID NO:
- 17)
- (d) an HVR-L1 sequence of RASQDVSTAVA;
- (SEQ ID NO:
- 18)
- (e) an HVR-L2 sequence of SASFLYS;
- and
- (SEQ ID NO:
- 19)
- (f) an HVR-L3 sequence of QQYLYHPAT.
A method for treating a non-small cell lung cancer in an individual comprising
- intravenously administering to the individual about 1200 mg of an anti-PD-L1 antibody every three weeks,
- wherein the anti-PD-L1 antibody is MPDL3280A.
A method for treating a metastatic non-small cell lung cancer in an individual comprising
- intravenously administering to the individual about 1200 mg of an anti-PD-L1 antibody every three weeks,
- wherein the anti-PD-L1 antibody is MPDL3280A.
A method of treating a sarcoma in an individual comprising intravenously administering to the individual about 15 mg/kg of an anti-PD-L1 antibody every three weeks, wherein the anti-PD-L1 antibody is MPDL3280A.
Dependencies are inferred from the claim text.